Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biopharmaceutical
|
| gptkbp:activeDuring |
adalimumab
|
| gptkbp:approves |
Crohn's disease
ankylosing spondylitis psoriasis rheumatoid arthritis ulcerative colitis juvenile idiopathic arthritis |
| gptkbp:brand |
adalimumab
|
| gptkbp:clinicalTrials |
numerous ongoing studies
recommended for certain conditions |
| gptkbp:community_service |
available
|
| gptkbp:contraindication |
heart failure
active infections history of tuberculosis serious infections liver problems malignancies allergy to adalimumab |
| gptkbp:customerFeedback |
generally positive
|
| gptkbp:developedBy |
AbbVie
|
| gptkbp:dosageForm |
every two weeks
|
| gptkbp:drugInterdiction |
subcutaneous absorption
auto-injector pre-filled syringe |
| gptkbp:embodiment |
Yes
|
| gptkbp:endOfLife |
approximately 15 days
|
| gptkbp:firstHeld |
loading dose
|
| gptkbp:follows |
maintenance dose
|
| gptkbp:formulation |
solution for injection
|
| gptkbp:hasCapacity |
available through AbbVie
|
| gptkbp:hasCompetitors |
biosimilars
|
| gptkbp:hasContribution |
over $20 billion
|
| gptkbp:hasPopulation |
adults and children
|
| gptkbp:healthcare |
important
important for efficacy important for prescribing |
| https://www.w3.org/2000/01/rdf-schema#label |
Humira
|
| gptkbp:impact |
long-term therapy
|
| gptkbp:interactsWith |
live vaccines
other immunosuppressants |
| gptkbp:is_monitored_by |
Yes
|
| gptkbp:is_used_in |
under study
|
| gptkbp:isIncorporatedIn |
Yes
|
| gptkbp:lastProduced |
2002
|
| gptkbp:localEconomy |
significant
|
| gptkbp:marketedAs |
over 100 countries
|
| gptkbp:offers |
high
|
| gptkbp:patentExpiration |
2023
|
| gptkbp:patentType |
Yes
|
| gptkbp:research |
significant investment
|
| gptkbp:researchFocus |
autoimmune diseases
|
| gptkbp:route |
subcutaneous injection
|
| gptkbp:safetyFeatures |
required
|
| gptkbp:sideEffect |
headache
nausea increased risk of infections injection site reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:triggerType |
TNF inhibitor
|